Sectoral Asset Management Inc. is an industry-leading specialist in managing global investment portfolios in the healthcare sector.
Business Model:
Revenue: $13.5M
Employees: 11-50
Address: 1010 Sherbrooke St. West,
City: Montreal
State: quebec
Zip: H3A 2R7
Country: CA
Sectoral Asset Management Inc. is an industry-leading specialist in managing global investment portfolios in the healthcare sector. Sectoral maintains offices in Montreal and Geneva and is a proud member of the State Street Global Alliance. They currently manage approximately US $4.0 billion in assets.
Contact Phone:
+15148498777
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2013 | RainDance Technologies | Series E | 0 |
2/2023 | Garuda Therapeutics | Series B | 0 |
11/2012 | Endosense | Series C | 40.3M |
9/2015 | Intellia Therapeutics | Series B | 0 |
5/2022 | Apnimed | Series C | 62.5M |
12/2022 | Apnimed | Series C | 79.7M |
6/2015 | Cogent Biosciences | Series B | 65M |
6/2022 | Mineralys Therapeutics | Series B | 0 |
7/2020 | CurvaFix | Series B | 10.7M |
1/2023 | Miach Orthopaedics | Series B | 0 |
6/2020 | Checkmate Pharmaceuticals | Series C | 85M |
5/2020 | Atea | Series D | 215M |
11/2016 | Shockwave Medical | Series C | 45M |
6/2020 | Prilenia | Series A | 62.5M |
10/2021 | Babylon | Post-IPO Equity | 0 |
8/2022 | Iantrek | Series B | 23M |
9/2021 | Garuda Therapeutics | Series A | 72M |
3/2009 | BioVex | Venture Round | 40M |
11/2018 | Aprea | Series C | 0 |
2/2021 | Pipeline Therapeutics | Series C | 0 |
8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
7/2017 | Effector Therapeutics | Series C | 38.6M |
8/2017 | Apellis Pharmaceuticals | Series E | 0 |
7/2021 | Turnstone Biologics | Series D | 0 |
5/2015 | Shockwave Medical | Series B | 40M |
12/2019 | Pipeline Therapeutics | Series B | 0 |
10/2009 | Endosense | Series B | 0 |
5/2015 | REGENXBIO | Series D | 0 |
2/2015 | Advaxis | Post-IPO Equity | 0 |
5/2023 | Boundless Bio | Series C | 0 |
3/2016 | Aprea | Series B | 50.6M |
2/2022 | Magnolia Medical Technologies | Venture Round | 0 |
2/2016 | Effector Therapeutics | Series B | 16M |
6/2016 | F2G | Series E | 60M |
1/2023 | Amolyt Pharma | Series C | 0 |
8/2015 | Advaxis | Post-IPO Equity | 25M |
10/2021 | Better Therapeutics | Post-IPO Equity | 0 |
9/2021 | Amolyt Pharma | Series B | 0 |
11/2013 | Endosense | Series C | 41.2M |
2/2021 | Viracta Therapeutics | Post-IPO Equity | 65M |
1/2021 | Neuros Medical | Series B | 0 |
1/2019 | HighLife | Series B | 36M |
11/2021 | Prilenia | Series B | 0 |
5/2018 | Rainier Therapeutics | Series B | 20M |
7/2017 | Simplify Medical | Series B | 21M |
2/2018 | Simplify Medical | Series B | 23M |
6/2022 | Mineralys Therapeutics | Series B | 0 |
5/2022 | Apnimed | Series C | 0 |
2/2022 | Magnolia Medical Technologies | Venture Round | 0 |
11/2021 | Prilenia | Series B | 0 |
10/2021 | Better Therapeutics | Post-IPO Equity | 0 |
10/2021 | Babylon | Post-IPO Equity | 0 |
9/2021 | Garuda Therapeutics | Series A | 0 |
9/2021 | Amolyt Pharma | Series B | 0 |
8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
7/2021 | Turnstone Biologics | Series D | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|